Literature DB >> 9302751

A candidate Ross River virus vaccine: preclinical evaluation.

J Aaskov1, L Williams, S Yu.   

Abstract

A killed Ross River virus vaccine is being developed in an effort to prevent the, ca 5000 cases of epidemic polyarthritis which occur in Australia each year. The symptoms of epidemic polyarthritis commonly last 30-40 weeks and 25% of patients have symptoms for a year or more. There is no cure. Although there was some strain to strain variation, particularly after a single injection, outbred and inbred strains of mice all produced significant levels of anti-Ross River virus antibody after intramuscular (i.m.) injection with 24 h BEI inactivated, sucrose gradient purified, Ross River virus vaccine. Mice immunized i.m. with two 20 micrograms doses of vaccine or live virus produced similar levels of neutralizing antibody but the reaction of IgG 2a and IgG 2b antibody from these two groups of mice to Ross River virus proteins in western blots differed. Antibody from BALB/c mice immunized with this vaccine neutralized all strains of Ross River virus tested, in vitro, albeit to different degrees.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9302751     DOI: 10.1016/s0264-410x(97)00051-0

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

Review 1.  Age has a role in driving host immunopathological response to alphavirus infection.

Authors:  Yi-Hao Chan; Lisa F P Ng
Journal:  Immunology       Date:  2017-08-23       Impact factor: 7.397

2.  An inactivated Ross River virus vaccine is well tolerated and immunogenic in an adult population in a randomized phase 3 trial.

Authors:  Nina Wressnigg; Maikel V W van der Velden; Daniel Portsmouth; Wolfgang Draxler; Maria O'Rourke; Peter Richmond; Stephen Hall; William J H McBride; Andrew Redfern; John Aaskov; P Noel Barrett; Gerald Aichinger
Journal:  Clin Vaccine Immunol       Date:  2014-12-24

Review 3.  Ross River virus transmission, infection, and disease: a cross-disciplinary review.

Authors:  D Harley; A Sleigh; S Ritchie
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

4.  Chikungunya virus arthritis in adult wild-type mice.

Authors:  Joy Gardner; Itaru Anraku; Thuy T Le; Thibaut Larcher; Lee Major; Pierre Roques; Wayne A Schroder; Stephen Higgs; Andreas Suhrbier
Journal:  J Virol       Date:  2010-06-02       Impact factor: 5.103

5.  Human monoclonal antibodies against Ross River virus target epitopes within the E2 protein and protect against disease.

Authors:  Laura A Powell; Julie M Fox; Nurgun Kose; Arthur S Kim; Mahsa Majedi; Robin Bombardi; Robert H Carnahan; James C Slaughter; Thomas E Morrison; Michael S Diamond; James E Crowe
Journal:  PLoS Pathog       Date:  2020-05-04       Impact factor: 6.823

6.  Sucrose density gradient centrifugation and cross-flow filtration methods for the production of arbovirus antigens inactivated by binary ethylenimine.

Authors:  Alyssa T Pyke; Debra A Phillips; Teck F Chuan; Greg A Smith
Journal:  BMC Microbiol       Date:  2004-01-14       Impact factor: 3.605

Review 7.  Ross River Virus: Many Vectors and Unusual Hosts Make for an Unpredictable Pathogen.

Authors:  Suzi B Claflin; Cameron E Webb
Journal:  PLoS Pathog       Date:  2015-09-03       Impact factor: 6.823

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.